Abcam’s MMP13 Human ELISA (Enzyme-Linked Immunosorbent Assay) kit is an in vitro enzyme linked immunosorbent assay for the quantitative measurement of Human MMP13 in plasma and cell culture supernatants.
This assay employs an antibody specific for Human MMP13 coated on a 96-well plate. Standards and samples are pipetted into the wells and MMP13 present in a sample is bound to the wells by the immobilized antibody. The wells are washed and biotinylated anti-Human MMP13 antibody is added. After washing away unbound biotinylated antibody, HRP-conjugated streptavidin is pipetted to the wells. The wells are again washed, a TMB substrate solution is added to the wells and color develops in proportion to the amount of MMP13 bound. The Stop Solution changes the color from blue to yellow, and the intensity of the color is measured at 450 nm.
The kit detects total MMP-13 levels.
We have not been able to detect endogenous Human MMP13 in normal serum with ab100605, only in serum spiked with Human MMP13.
Degrades collagen type I. Does not act on gelatin or casein. Could have a role in tumoral process.
Seems to be specific to breast carcinomas.
Defects in MMP13 are the cause of spondyloepimetaphyseal dysplasia Missouri type (SEMD-MO) [MIM:602111]. A bone disease characterized by moderate to severe metaphyseal changes, mild epiphyseal involvement, rhizomelic shortening of the lower limbs with bowing of the femora and/or tibiae, coxa vara, genu varum and pear-shaped vertebrae in childhood. Epimetaphyseal changes improve with age. Defects in MMP13 are the cause of metaphyseal anadysplasia type 1 (MANDP1) [MIM:602111]. Metaphyseal anadysplasia consists of an abnormal bone development characterized by severe skeletal changes that, in contrast with the progressive course of most other skeletal dysplasias, resolve spontaneously with age. Clinical characteristics are evident from the first months of life and include slight shortness of stature and a mild varus deformity of the legs. Patients attain a normal stature in adolescence and show improvement or complete resolution of varus deformity of the legs and rhizomelic micromelia.
Belongs to the peptidase M10A family. Contains 4 hemopexin-like domains.
The conserved cysteine present in the cysteine-switch motif binds the catalytic zinc ion, thus inhibiting the enzyme. The dissociation of the cysteine from the zinc ion upon the activation-peptide release activates the enzyme.
Secreted > extracellular space > extracellular matrix.
Alexander K et al. Levels of Matrix Metalloproteinases in Arthroplasty Patients and Their Correlation With Inflammatory and Thrombotic Activation Processes. Clin Appl Thromb Hemost22:441-6 (2016).
Read more (PubMed: 27052781) »
Zeng JZ et al. Increased receptor activator of nuclear factor ?ß ligand/osteoprotegerin ratio exacerbates cartilage destruction in osteoarthritis in vitro. Exp Ther Med12:2778-2782 (2016).
Read more (PubMed: 27698783) »